The overall goal of this academic-industrial partnership is to improve the clinical imaging assessment of prostate cancer patients by creating a clinically optimized and validated commercial 3T multi-parametric (T2 MRI, 1H and hyperpolarized 13C MRSI, DTI and DCE) imaging exam for widespread distribution. The clinical rationale for the proposed studies is that prostate cancer management, more than many cancers, requires accurate imaging information to select the most appropriate treatment for individual patients and for assessing response to therapy. This is due to the pathologic and biologic complexity of the human prostate and prostate cancer. This complexity results in questions of whether and how to treat individual prostate cancer patients. Additionally, this complexity demands state-of-the-art high spatial resolution multiparametric MR imaging and spectroscopy techniques to accurately assess disease status in individual patients. While recent advances in the development of anatomic, metabolic and physiologic imaging methods are having a significant impact in clinical prostate cancer research studies, a robust commercially available multiparametric 3T (T2 MRI, 1H MRSI, DTI, and DCE) magnetic resonance imaging exam does not exist. In this project, we also propose to develop and translate into patient studies hyperpolarized 13C MR, a new metabolic imaging technique that has shown potential for greatly advancing prostate cancer imaging. The proton MR techniques have been developed through an NCI-funded Bioengineering Research Partnership development project and are now ready for clinical validation studies. The hyperpolarized 13C MR is at an earlier developmental stage nearing patient studies and now requires this academic-industrial partnership with both extensive MR engineering and clinical expertise to move this promising new metabolic imaging technology forward for patient evaluation studies. This academic-industrial partnership between a major MR manufacturer and an experienced prostate cancer clinical-research group is critical for the creation of new clinical imaging tools for better characterizing the presence, extent, aggressiveness, and response to therapy of this very common and biologically diverse cancer.

Public Health Relevance

The overall goal of this academic-industrial partnership is to improve the clinical imaging assessment of prostate cancer patients by creating a clinically optimized and validated commercial 3T multi-parametric (T2 MRI, 1H and hyperpolarized 13C MRSI, DTI and DCE) imaging exam for widespread distribution and use in multi-center clinical trials. The clinical rationale is that prostate cancers demonstrate a tremendous range in biologic diversity, and an urgent need exists to develop non-invasive imaging biomarkers for improved prostate cancer patient-specific treatment planning and early assessment of therapeutic failure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA137207-05
Application #
8690790
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Menkens, Anne E
Project Start
2010-08-09
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Westphalen, Antonio C; Noworolski, Susan M; Harisinghani, Mukesh et al. (2016) High-Resolution 3-T Endorectal Prostate MRI: A Multireader Study of Radiologist Preference and Perceived Interpretive Quality of 2D and 3D T2-Weighted Fast Spin-Echo MR Images. AJR Am J Roentgenol 206:86-91
Korn, Natalie; Kurhanewicz, John; Banerjee, Suchandrima et al. (2015) Reduced-FOV excitation decreases susceptibility artifact in diffusion-weighted MRI with endorectal coil for prostate cancer detection. Magn Reson Imaging 33:56-62
Salgaonkar, Vasant A; Prakash, Punit; Rieke, Viola et al. (2014) Model-based feasibility assessment and evaluation of prostate hyperthermia with a commercial MR-guided endorectal HIFU ablation array. Med Phys 41:033301
Chang, Stephanie T; Westphalen, Antonio C; Jha, Priyanka et al. (2014) Endorectal MRI and MR spectroscopic imaging of prostate cancer: developing selection criteria for MR-guided focal therapy. J Magn Reson Imaging 39:519-25
Muller, Berrend G; Futterer, Jurgen J; Gupta, Rajan T et al. (2014) The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int 113:218-27
Zhang, V Y; Westphalen, A; Delos Santos, L et al. (2014) The role of metabolic imaging in radiation therapy of prostate cancer. NMR Biomed 27:100-11
Flavell, Robert R; Westphalen, Antonio C; Liang, Carmin et al. (2014) Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance. Abdom Imaging 39:1027-35
Jung, Adam J; Westphalen, Antonio C; Kurhanewicz, John et al. (2014) Clinical utility of endorectal MRI-guided prostate biopsy: preliminary experience. J Magn Reson Imaging 40:314-23
Starobinets, Olga; Guo, Richard; Simko, Jeffry P et al. (2014) Semiautomatic registration of digital histopathology images to in vivo MR images in molded and unmolded prostates. J Magn Reson Imaging 39:1223-9
Crehange, Gilles; Krishnamurthy, Devan; Cunha, J Adam et al. (2013) Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: implications for focal salvage brachytherapy. Radiother Oncol 109:246-50

Showing the most recent 10 out of 27 publications